Home/Pipeline/TST002 (Blosozumab)

TST002 (Blosozumab)

Osteoporosis

Phase 1Active

Key Facts

Indication

Osteoporosis

Phase

Phase 1

Status

Active

Company

Transcenta Therapeutics

About Transcenta Therapeutics

A global, fully integrated biotherapeutics company developing differentiated and affordable antibody biologics for oncology and other serious diseases.

View full company profile

Therapeutic Areas

Oncology Musculoskeletal Renal

Other Osteoporosis Drugs

Drug	Company	Phase	Status
Biosimilar to Prolia® (denosumab)	Teva	Approved/Under Review	Launched in EU, under review in US
Teriparatide	Epygen Biotech	Not Disclosed	Active
AGA2118	Angitia Biopharmaceuticals	Phase 2	Active
Teriparatide (PTH 1-34) Process	Numaferm	Commercial	Active
Recombinant Teriparatide	Paras Biopharmaceuticals Finland	Pre-clinical	Active
Stoboclo®/Osenvelt®	Celltrion	Marketed	Approved
SHR-1222	Jiangsu Hengrui Medicine	Phase III	Active
Biosimilar Denosumab	Richter Gedeon	Phase III	Active
Teriparatide Injection	Amphastar Pharmaceuticals	Marketed	Generic (Launched)